Company profile · Sponsor
BIAL
BIAL - Portela & Ca
- Pipeline
- 4
- Drugs
- 0
- Patents
- 0
Quick answer
BIAL (EB084CF) is a pharma company. headquartered in EU. listed on EMA. NovaPharmaNews links 4 pipeline programs, 0 drugs, and 0 patents to this profile..
Company facts
Pipeline (4)
Search pipeline →-
Bioequivalence of Amoxicillin and Clavulanic Acid 250 mg/62.5 mg/5 mL Powder for Oral Suspension versus Augmentin® Forte 250 mg/62.5 mg/5 mL Powder for Oral Suspension in Healthy Participants Under Fed Conditions
BIAL
No medical condition.
1 trial -
Bioequivalence of Amoxicillin and Clavulanic Acid 500 mg/125 mg Film-Coated Tablets in Healthy Participants Under Fed Conditions.
BIAL
No medical condition.
1 trial -
Bioequivalence of Amoxicillin and Clavulanic Acid 875 mg/125 mg Film-Coated Tablets in Healthy Participants Under Fed Conditions.
BIAL
No medical condition.
1 trial -
Drug-Drug Interaction Study With BIA 28-6156 and Clarithromycin, Midazolam, and Dabigatran Etexilate in Healthy Participants
BIAL
Healthy volunteers
1 trial
Frequently asked questions
What is BIAL?
BIAL (EB084CF) is a pharma company. headquartered in EU. listed on EMA. NovaPharmaNews links 4 pipeline programs, 0 drugs, and 0 patents to this profile..
What pipeline programs does BIAL sponsor?
We track 4 ClinicalTrials.gov-linked programs for BIAL, including Bioequivalence of Amoxicillin and Clavulanic Acid 250 mg/62.5 mg/5 mL Powder for Oral Suspension versus Augmentin® Forte 250 mg/62.5 mg/5 mL Powder for Oral Suspension in Healthy Participants Under Fed Conditions and 3 more. Open each program for phase, modality, NCT IDs, and indication details.
Where does BIAL company data come from?
Profiles combine SEC EDGAR (CIK/ticker), ClinicalTrials.gov sponsor links, FDA drug records, and USPTO patent metadata. See our data sources page. This profile is for professional reference, not investment advice.